362 related articles for article (PubMed ID: 26890396)
1. Differentially methylated genes and androgen receptor re-expression in small cell prostate carcinomas.
Kleb B; Estécio MR; Zhang J; Tzelepi V; Chung W; Jelinek J; Navone NM; Tahir S; Marquez VE; Issa JP; Maity S; Aparicio A
Epigenetics; 2016 Mar; 11(3):184-93. PubMed ID: 26890396
[TBL] [Abstract][Full Text] [Related]
2. Methyltransferase inhibitor adenosine dialdehyde suppresses androgen receptor expression and prostate cancer growth.
Shiota M; Takeuchi A; Yokomizo A; Kashiwagi E; Tatsugami K; Naito S
J Urol; 2012 Jul; 188(1):300-6. PubMed ID: 22608750
[TBL] [Abstract][Full Text] [Related]
3. SMYD3 as an oncogenic driver in prostate cancer by stimulation of androgen receptor transcription.
Liu C; Wang C; Wang K; Liu L; Shen Q; Yan K; Sun X; Chen J; Liu J; Ren H; Liu H; Xu Z; Hu S; Xu D; Fan Y
J Natl Cancer Inst; 2013 Nov; 105(22):1719-28. PubMed ID: 24174655
[TBL] [Abstract][Full Text] [Related]
4. Effect of histone deacetylase and DNA methyltransferase inhibitors on the expression of the androgen receptor gene in androgen-independent prostate cancer cell lines.
Fialova B; Smesny Trtkova K; Paskova L; Langova K; Kolar Z
Oncol Rep; 2013 May; 29(5):2039-45. PubMed ID: 23503510
[TBL] [Abstract][Full Text] [Related]
5. Epigenetic modulation of AR gene expression in prostate cancer DU145 cells with the combination of sodium butyrate and 5'-Aza-2'-deoxycytidine.
Fialova B; Luzna P; Gursky J; Langova K; Kolar Z; Trtkova KS
Oncol Rep; 2016 Oct; 36(4):2365-74. PubMed ID: 27499010
[TBL] [Abstract][Full Text] [Related]
6. Methylation of the androgen receptor promoter CpG island is associated with loss of androgen receptor expression in prostate cancer cells.
Jarrard DF; Kinoshita H; Shi Y; Sandefur C; Hoff D; Meisner LF; Chang C; Herman JG; Isaacs WB; Nassif N
Cancer Res; 1998 Dec; 58(23):5310-4. PubMed ID: 9850055
[TBL] [Abstract][Full Text] [Related]
7. Patient-derived castration-resistant prostate cancer model revealed CTBP2 upregulation mediated by OCT1 and androgen receptor.
Obinata D; Takayama K; Lawrence MG; Funakoshi D; Hara M; Niranjan B; Teng L; Taylor RA; Risbridger GP; Takahashi S; Inoue S
BMC Cancer; 2024 May; 24(1):554. PubMed ID: 38698344
[TBL] [Abstract][Full Text] [Related]
8. KDM8/JMJD5 as a dual coactivator of AR and PKM2 integrates AR/EZH2 network and tumor metabolism in CRPC.
Wang HJ; Pochampalli M; Wang LY; Zou JX; Li PS; Hsu SC; Wang BJ; Huang SH; Yang P; Yang JC; Chu CY; Hsieh CL; Sung SY; Li CF; Tepper CG; Ann DK; Gao AC; Evans CP; Izumiya Y; Chuu CP; Wang WC; Chen HW; Kung HJ
Oncogene; 2019 Jan; 38(1):17-32. PubMed ID: 30072740
[TBL] [Abstract][Full Text] [Related]
9. Modeling a lethal prostate cancer variant with small-cell carcinoma features.
Tzelepi V; Zhang J; Lu JF; Kleb B; Wu G; Wan X; Hoang A; Efstathiou E; Sircar K; Navone NM; Troncoso P; Liang S; Logothetis CJ; Maity SN; Aparicio AM
Clin Cancer Res; 2012 Feb; 18(3):666-77. PubMed ID: 22156612
[TBL] [Abstract][Full Text] [Related]
10. Global methylation analysis identifies PITX2 as an upstream regulator of the androgen receptor and IGF-I receptor genes in prostate cancer.
Schayek H; Bentov I; Jacob-Hirsch J; Yeung C; Khanna C; Helman LJ; Plymate SR; Werner H
Horm Metab Res; 2012 Jun; 44(7):511-9. PubMed ID: 22495974
[TBL] [Abstract][Full Text] [Related]
11. Scaffold attachment factor B1 regulates the androgen receptor in concert with the growth inhibitory kinase MST1 and the methyltransferase EZH2.
Mukhopadhyay NK; Kim J; You S; Morello M; Hager MH; Huang WC; Ramachandran A; Yang J; Cinar B; Rubin MA; Adam RM; Oesterreich S; Di Vizio D; Freeman MR
Oncogene; 2014 Jun; 33(25):3235-45. PubMed ID: 23893242
[TBL] [Abstract][Full Text] [Related]
12. Identification of Therapeutic Vulnerabilities in Small-cell Neuroendocrine Prostate Cancer.
Corella AN; Cabiliza Ordonio MVA; Coleman I; Lucas JM; Kaipainen A; Nguyen HM; Sondheim D; Brown LG; True LD; Lee JK; MacPherson D; Nghiem P; Gulati R; Morrissey C; Corey E; Nelson PS
Clin Cancer Res; 2020 Apr; 26(7):1667-1677. PubMed ID: 31806643
[TBL] [Abstract][Full Text] [Related]
13. Neuroendocrine differentiation in usual-type prostatic adenocarcinoma: Molecular characterization and clinical significance.
Kaur H; Samarska I; Lu J; Faisal F; Maughan BL; Murali S; Asrani K; Alshalalfa M; Antonarakis ES; Epstein JI; Joshu CE; Schaeffer EM; Mosquera JM; Lotan TL
Prostate; 2020 Sep; 80(12):1012-1023. PubMed ID: 32649013
[TBL] [Abstract][Full Text] [Related]
14. The association between histone 3 lysine 27 trimethylation (H3K27me3) and prostate cancer: relationship with clinicopathological parameters.
Ngollo M; Lebert A; Dagdemir A; Judes G; Karsli-Ceppioglu S; Daures M; Kemeny JL; Penault-Llorca F; Boiteux JP; Bignon YJ; Guy L; Bernard-Gallon D
BMC Cancer; 2014 Dec; 14():994. PubMed ID: 25535400
[TBL] [Abstract][Full Text] [Related]
15. Resistance to androgen receptor signaling inhibition does not necessitate development of neuroendocrine prostate cancer.
Brennen WN; Zhu Y; Coleman IM; Dalrymple SL; Antony L; Patel RA; Hanratty B; Chikarmane R; Meeker AK; Zheng SL; Hooper JE; Luo J; De Marzo AM; Corey E; Xu J; Yegnasubramanian S; Haffner MC; Nelson PS; Nelson WG; Isaacs WB; Isaacs JT
JCI Insight; 2021 Apr; 6(8):. PubMed ID: 33724955
[TBL] [Abstract][Full Text] [Related]
16. Demethylation of the miR-146a promoter by 5-Aza-2'-deoxycytidine correlates with delayed progression of castration-resistant prostate cancer.
Wang X; Gao H; Ren L; Gu J; Zhang Y; Zhang Y
BMC Cancer; 2014 May; 14():308. PubMed ID: 24885368
[TBL] [Abstract][Full Text] [Related]
17. DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Poirier JT; Gardner EE; Connis N; Moreira AL; de Stanchina E; Hann CL; Rudin CM
Oncogene; 2015 Nov; 34(48):5869-78. PubMed ID: 25746006
[TBL] [Abstract][Full Text] [Related]
18. Increased expression of androgen receptor coregulator MAGE-11 in prostate cancer by DNA hypomethylation and cyclic AMP.
Karpf AR; Bai S; James SR; Mohler JL; Wilson EM
Mol Cancer Res; 2009 Apr; 7(4):523-35. PubMed ID: 19372581
[TBL] [Abstract][Full Text] [Related]
19. Circular RNAs add diversity to androgen receptor isoform repertoire in castration-resistant prostate cancer.
Cao S; Ma T; Ungerleider N; Roberts C; Kobelski M; Jin L; Concha M; Wang X; Baddoo M; Nguyen HM; Corey E; Fazli L; Ledet E; Zhang R; Silberstein JL; Zhang W; Zhang K; Sartor O; Dong X; Flemington EK; Dong Y
Oncogene; 2019 Nov; 38(45):7060-7072. PubMed ID: 31409897
[TBL] [Abstract][Full Text] [Related]
20. Regulation and methylation of tumor suppressor miR-124 by androgen receptor in prostate cancer cells.
Chu M; Chang Y; Guo Y; Wang N; Cui J; Gao WQ
PLoS One; 2015; 10(4):e0116197. PubMed ID: 25860954
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
